Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

被引：2
|
作者：
Kalff, Anna
Kennedy, Nola
Smiley, Angela
Prince, H. Miles
Roberts, Andrew W.
Bradstock, Kenneth F.
Lourenco, Richard De Abreu
Spencer, Andrew
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.537.537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
537
引用
收藏
页数：2
相关论文
共 29 条
  • [1] A tissue Microarray classification in multiple myeloma (MM) predicts survival post autologous stem cell transplant (ASCT)
    Bahlis, Nizar
    Stewart, Douglas
    Shin, Brian
    Mansoor, Adnan
    BLOOD, 2007, 110 (11) : 138A - 139A
  • [2] First analysis of the Australasian leukaemia and lymphoma group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6).
    Spencer, Andrew
    Prince, Miles
    Roberts, Andrew W.
    Bradstock, Kenneth F.
    Prosser, Ian W.
    BLOOD, 2006, 108 (11) : 22A - 22A
  • [3] Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study
    Kalff, Anna
    Kennedy, Nola
    Smiley, Angela
    Prince, H. Miles
    Roberts, Andrew W.
    Bradstock, Kenneth
    De Abreu Loureno, Richard
    Frampton, Chris
    Spencer, Andrew
    LANCET HAEMATOLOGY, 2014, 1 (03): : E112 - E119
  • [4] Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT)
    Kostakoglu, Lale
    Dingli, David
    Beksac, Meral
    Zamagni, Elena
    Mark, Tomer Martin
    Chari, Ajai
    Elliott, Brian M.
    Lowe, Val J.
    Ozkan, Elgin
    Nanni, Cristina
    Kucuk, Ozlem
    Fanti, Stefano
    Coleman, Morton
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Steroid Refractoriness, but Not Rapidity of Response, to Induction Therapy Predicts for Outcome Post-Autologous Stem Cell Transplant (ASCT) in Patients (Pts) with Multiple Myeloma (MM)
    Prica, Anca
    Trieu, Young
    Xu, Wei
    Reece, Donna E.
    Trudel, Suzanne
    Kukreti, Vishal
    Anglin, Peter
    Chen, Christine
    BLOOD, 2008, 112 (11) : 1138 - 1139
  • [6] Final results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM).
    Thomas, Sheeba K.
    George, Jamie S.
    de Partovi, Claudia M. Morales
    Feng, Lei
    Morphey, Ashley S.
    Becnel, Melody R.
    Kaufman, Gregory P.
    Lee, Hans C.
    Manasanch, Elisabet Esteve
    Patel, Krina K.
    Pasvolsky, Oren
    Ye, Jing Christine
    Amini, Behrang
    Qazilbash, Muzaffar H.
    Bashir, Qaiser
    Crumpton, Brandon N.
    Stafford, Mildred M.
    Johnson, Ralph J., III
    Weber, Donna M.
    Orlowski, Robert Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Over expression of cyclin B2 predicts poor clinical outcome among multiple myeloma (MM) patients (pts) post autologous stem cell transplant (ASCT)
    Mansoor, A.
    Stewart, D. A.
    Shin, B.
    Roland, B.
    Rad, M. T. S.
    Magliocco, A.
    Bahlis, N.
    MODERN PATHOLOGY, 2008, 21 : 264A - 264A
  • [8] Over expression of cyclin B2 predicts poor clinical outcome among multiple myeloma (MM) patients (pts) post autologous stem cell transplant (ASCT)
    Mansoor, A.
    Stewart, D. A.
    Shin, B.
    Roland, B.
    Rod, M. T. S.
    Magliocco, A.
    Bahlis, N.
    LABORATORY INVESTIGATION, 2008, 88 : 264A - 264A
  • [9] Comparison of Outcomes Post Autologous Stem Cell Transplant (ASCT) in Patients with Multiple Myeloma (MM) Based on Dosage of Melphalan (mel) As Part of Conditioning Therapy: Single Institutional Experience of a Large Study Group
    Sharma, Nidhi
    Zhao, Qiuhong
    Khan, Abdullah
    Bumma, Naresh
    Chaudhry, Maria
    Rosko, Ashley
    Benson, Don M.
    Efebera, Yvonne A.
    Devarakonda, Srinivas
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S233 - S233
  • [10] A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.
    Quach, Hang
    Lasica, Masa
    Routledge, David
    Kalff, Anna
    Lim, Andrew
    Low, Michael
    Estell, Jane A.
    Sidiqi, M. Hasib
    Campbell, Philip
    Eek, Richard Wilhelm
    Lai, Hock C.
    McCaughan, Georgia J.
    D'Rozario, James
    Browlett, Peter
    Rajagopal, Rajeev
    Heenan, Jessica
    Murphy, Nicholas E.
    Renwick, William
    Huan, Georgina
    Mollee, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
123